14 research outputs found
Determinants of high somatic-cell count prevalence in dairy herds practicing teat dipping and dry cow therapy and with no evidence of Streptococcus-agalactiae on repeated bulk tank milk examination
No full textPT: J; CR: 1982, SAS USERS GUIDE STAT BODOH GW, 1976, J DAIRY SCI, V59, P1119 BRAMLEY AJ, 1984, J DAIRY RES, V51, P481 BUSHNELL RB, 1984, 23RD P ANN M NAT MAS, P31 BUSHNELL RB, 1985, 24TH P ANN M NAT MAS, P45 DOHOO IR, 1982, CAN VET J, V23, P119 GALTON DM, 1984, 17TH P ANN C AM ASS, P108 GOODHOPE RG, 1980, CAN J COMP MED, V44, P351 HARVEY WR, 1982, J ANIM SCI, V54, P1067 HOARE RJT, 1979, AUST J DAIRY TECHNOL, V34, P91 HUESTON WD, 1987, PREV VET MED, V4, P447 KIRK JH, 1984, COMP CONT EDUC PRACT, V6, S237 LESLIE KE, 1983, COMPEND CONTIN ED P, V5, S601 LINDSTROM UB, 1983, ACTA AGR SCAND, V33, P389 MEIN GA, 1977, AUST J DAIRY TECHNOL, V32, P81 MINETT FC, 1933, J COMP PATH THERAP, V46, P131 MOXLEY JE, 1978, J DAIRY SCI, V61, P1637 NEWMAN LE, 1973, AM J VET RES, V34, P979 PEARSON JKL, 1972, VET REC, V91, P615 POSTLE DS, 1968, AM J VET RES, V29, P669 POSTLE DS, 1971, J MILK FOOD TECH, V34, P517 SMITH KL, 1983, J DAIRY SCI, V66, P1790 STABLEFORTH AW, 1935, J COMP PATHOL, V48, P300; NR: 23; TC: 11; J9: PREV VET MED; PG: 12; GA: DU955Source type: Electronic(1
The negative bidirectional interaction between climate change and the prevalence and care of liver disease:A joint BSG, BASL, EASL, and AASLD commentary
No full textThe negative bidirectional interaction between climate change and the prevalence and care of liver disease:A Joint BSG, BASL, EASL, and AASLD commentary
No full text
Iatrogenic portobiliary fistula complicating endoscopic stenting of a pancreatic cyst, with possible carcinoma: a case report.
No full textTraumatic posterior shoulder dislocation: A case with modification of Gerber procedure for humeral head reconstruction at 10-year follow-up
No full textWe report a case of acute traumatic posterior shoulder dislocation in a 41-year-old patient, which we treated surgically by a modification of the procedure described by Gerber for humeral head reconstruction in such cases. The diagnosis was confirmed by CT scan, which also helped us to assess the size of the antero-medial humeral head defect or impaction secondary to the dislocation; the size of this defect being a determinant element for the indication. Because the shoulder was unstable after closed reduction and almost 50percent of the humeral head was impacted, we carried out a surgical treatment using an original technique as mentioned above. Radiologic and surgical features of acute traumatic posterior shoulder dislocation are discussed with special emphasis on diagnosis, indications and surgical aspects of this rare lesion, which represent 2-4percent of acute traumatic shoulder dislocations. © 2008 Springer-Verlag.ARNDT JH, 1965, AMER J ROENTGENOL RA, V94, P639; BLOOM MH, 1967, J BONE JOINT SURG AM, VA 49, P943; CISTERNINO SJ, 1978, AM J ROENTGENOL, V130, P951; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; Dubousset J, 1967, Rev Chir Orthop Reparatrice Appar Mot, V53, P65; FINKELSTEIN JA, 1995, J ORTHOP TRAUMA, V9, P190; Gerber C, 1991, CAHIERS ENSEIGNEMENT, V40, P223; GERBER C, 2006, J BONE JOINT SURG AM, V87, P1739; GERBER C, 1988, CAHIERS ENSEIGNEMENT, V33, P51; Gerber C, 1996, J BONE JOINT SURG AM, V78A, P376; HAWKINS RJ, 1987, J BONE JOINT SURG AM, V69A, P9; Kaar TK, 1999, J BONE JOINT SURG AM, V81A, P708; MANSAT M, 1988, REV CHIR ORTHOP, V74, P257; MCLAUGHLIN HL, 1952, J BONE JOINT SURG AM, V34-A, P584; PICARD F, 1993, JOURN LYONN EP LYON; Picard F, 1998, REV CHIR ORTHOP, V84, P217; RANDELLI M, 1988, 2 C EUR SOC SHOULD E; RICHARDS RH, 1989, INJURY, V20, P297, DOI 10.1016-0020-1383(89)90174-5; Samilson R L, 1964, Clin Orthop Relat Res, V32, P69; STABLEFORTH PG, 1992, J BONE JOINT SURG BR, V74, P579; Swamy G, 1998, J TRAUMA, V44, P377, DOI 10.1097-00005373-199802000-00026; VANDENBUSCHE E, 1996, CAHIER SOFCOT, V56, P238; VANDENBUSSCHE E, 1994, CAHIERS ENSEIGNEMENT, V49, P75; VASTAMAKI M, 1980, ACTA ORTHOP SCAND, V51, P479, DOI 10.3109-17453678008990827; VICHARD P, 1981, REV CHIR ORTHOP, V67, P71; VICHARD P, 1988, CAHIERS ENSEIGNEMENT, V31, P179; WALCH G, 1990, REV CHIR ORTHOP, V76, P5460
Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A-Z
No full textThe History of Modern Biomedicine Research Group hosted its first Witness Seminar, on monoclonal antibodies, in 1993. Since then more than sixty such meetings have been held, the most recent on migraine in 2013. These all sought to go behind-the-scenes of contemporary biomedicine to find out ‘what really happened’. In this, the Group’s twenty-first anniversary year, we are delighted to present our fiftieth Witness Seminar volume Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A–Z. Comprising a series of extracts from previous volumes, contributors include clinicians, scientists, patients and numerous others involved in modern biomedicine, in the UK and beyond. Topics range from ‘age discrimination’ to ‘Zantac’, and feature memories from every decade between the 1930s and the present.The History of Modern Biomedicine Research Group hosted its first Witness Seminar, on monoclonal antibodies, in 1993. Since then more than sixty such meetings have been held, the most recent on migraine in 2013. These all sought to go behind-the-scenes of contemporary biomedicine to find out ‘what really happened’. In this, the Group’s twenty-first anniversary year, we are delighted to present our fiftieth Witness Seminar volume Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A–Z. Comprising a series of extracts from previous volumes, contributors include clinicians, scientists, patients and numerous others involved in modern biomedicine, in the UK and beyond. Topics range from ‘age discrimination’ to ‘Zantac’, and feature memories from every decade between the 1930s and the present.The History of Modern Biomedicine Research Group hosted its first Witness Seminar, on monoclonal antibodies, in 1993. Since then more than sixty such meetings have been held, the most recent on migraine in 2013. These all sought to go behind-the-scenes of contemporary biomedicine to find out ‘what really happened’. In this, the Group’s twenty-first anniversary year, we are delighted to present our fiftieth Witness Seminar volume Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A–Z. Comprising a series of extracts from previous volumes, contributors include clinicians, scientists, patients and numerous others involved in modern biomedicine, in the UK and beyond. Topics range from ‘age discrimination’ to ‘Zantac’, and feature memories from every decade between the 1930s and the present.The History of Modern Biomedicine Research Group hosted its first Witness Seminar, on monoclonal antibodies, in 1993. Since then more than sixty such meetings have been held, the most recent on migraine in 2013. These all sought to go behind-the-scenes of contemporary biomedicine to find out ‘what really happened’. In this, the Group’s twenty-first anniversary year, we are delighted to present our fiftieth Witness Seminar volume Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A–Z. Comprising a series of extracts from previous volumes, contributors include clinicians, scientists, patients and numerous others involved in modern biomedicine, in the UK and beyond. Topics range from ‘age discrimination’ to ‘Zantac’, and feature memories from every decade between the 1930s and the present.The History of Modern Biomedicine Research Group hosted its first Witness Seminar, on monoclonal antibodies, in 1993. Since then more than sixty such meetings have been held, the most recent on migraine in 2013. These all sought to go behind-the-scenes of contemporary biomedicine to find out ‘what really happened’. In this, the Group’s twenty-first anniversary year, we are delighted to present our fiftieth Witness Seminar volume Monoclonal Antibodies to Migraine: Witnesses to modern biomedicine, an A–Z. Comprising a series of extracts from previous volumes, contributors include clinicians, scientists, patients and numerous others involved in modern biomedicine, in the UK and beyond. Topics range from ‘age discrimination’ to ‘Zantac’, and feature memories from every decade between the 1930s and the present.Wellcome Trust
Reducing the environmental footprint of gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) position statement
No full textClimate change and the destruction of ecosystems by human activities are among the greatest challenges of the 21st century and require urgent action. Health care activities significantly contribute to the emission of greenhouse gases and waste production, with gastrointestinal (GI) endoscopy being one of the largest contributors. This Position Statement aims to raise awareness of the ecological footprint of GI endoscopy and provides guidance to reduce its environmental impact. The European Society of Gastrointestinal Endoscopy (ESGE) and the European Society of Gastroenterology and Endoscopy Nurses and Associates (ESGENA) outline suggestions and recommendations for health care providers, patients, governments, and industry. MAIN STATEMENTS 1: GI endoscopy is a resource-intensive activity with a significant yet poorly assessed environmental impact. 2: ESGE-ESGENA recommend adopting immediate actions to reduce the environmental impact of GI endoscopy. 3: ESGE-ESGENA recommend adherence to guidelines and implementation of audit strategies on the appropriateness of GI endoscopy to avoid the environmental impact of unnecessary procedures. 4: ESGE-ESGENA recommend the embedding of reduce, reuse, and recycle programs in the GI endoscopy unit. 5: ESGE-ESGENA suggest that there is an urgent need to reassess and reduce the environmental and economic impact of single-use GI endoscopic devices. 6: ESGE-ESGENA suggest against routine use of single-use GI endoscopes. However, their use could be considered in highly selected patients on a case-by-case basis. 7: ESGE-ESGENA recommend inclusion of sustainability in the training curricula of GI endoscopy and as a quality domain. 8: ESGE-ESGENA recommend conducting high quality research to quantify and minimize the environmental impact of GI endoscopy. 9: ESGE-ESGENA recommend that GI endoscopy companies assess, disclose, and audit the environmental impact of their value chain. 10: ESGE-ESGENA recommend that GI endoscopy should become a net-zero greenhouse gas emissions practice by 2050.status: Publishe
Hetrocyclic methacrylate systems as vehicles for the release of active species.
No full textPhDThe room temperature polymerising heterocyclic polymer system, poly(ethyl
methacrylate)/tetrahydrofurfuryl methacrylate (PEM/THFM) has been shown
previously to be biocompatible and supported tissue repair, specifically for bone
and cartilage, and biologically inert when in contact with the dental pulp. It
proved more effective, than other glassy methacrylates in the release of active
species.
The PEM/THFM system is a rigid material. The aim of this study was to develop
and characterise the use of this system as a flexible patch, for application and
retention to the buccal mucosa, thus facilitating sustained regulated release.
Model species, dextrans, were used to represent macromolecular drugs whereby
the effect of molecular weight could be studied. N-methyl pyrrolidone was added
to the polymer system as a biocompatible plasticiser to enhance molecular
mobility, and hence the transport of species. The effect of the addition of chitosan
was also studied, due to its bioadhesiveness and permeation enhancing ability.
A range of systems was investigated both in terms of water and species release.
The release of the agent was measured by a fluorometer, the leachable
components by HPLC and Confocal microscopy demonstrated the transport of
water and active species through the system. Immunological and viability studies
established whether the leachants or released components of the polymeric
systems had an inflammatory or irritant action on `in vitro' stratified epithelium.
The addition of N-methyl pyrrolidone, dextran and chitosan substantially
increased water uptake, thus affecting the release kinetics. Analysis of the
kinetics of water uptake showed Case I, combination of Case I and Case II, and
Case II kinetics, depending on the systems studied. Dextran release was largely
diffusion controlled, from which diffusion coefficients were calculated; the
amount released varied between the systems studied
